Tai San Noah Lim
Director/Board Member presso Mirxes Holding Co., Ltd.
Profilo
Tai San Noah Lim is an Independent Non-Executive Director at Mirxes Holding Co., Ltd.
He holds a graduate degree and a doctorate from the University of Pennsylvania, which he received in 2003 and 2005 respectively.
He also holds an undergraduate degree from the National University of Singapore, which he received in 1999.
Posizioni attive di Tai San Noah Lim
| Società | Posizione | Inizio |
|---|---|---|
Mirxes Holding Co., Ltd.
 Mirxes Holding Co., Ltd. Financial ConglomeratesFinance Mirxes Holding Co., Ltd. operates as an investment holding company. It is engaged in developing and commercializing blood-based miRNA test kit products for the early detection of cancer and other diseases. The firm’s business segments include Infectious Diseases and Early Detection and Precision Multi-Omics. The Infectious Diseases segment engages in development, manufacture, supply of diagnostic kits and provision of infectious disease clinical testing. The Early Detection and Precision Multi-Omics involves in Development, manufacture, supply of diagnostic & life sciences products, and provision of research profiling, clinical testing and clinical services. The company was founded by Too Heng Phon, Zhou Lihan and Zou Ruiyang in 2014 and is headquartered in Singapore. | Director/Board Member | 01/01/2021 |
Formazione di Tai San Noah Lim
| University of Pennsylvania | Doctorate Degree |
| National University of Singapore | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 1 |
|---|---|
Mirxes Holding Co., Ltd.
Mirxes Holding Co., Ltd. Financial ConglomeratesFinance Mirxes Holding Co., Ltd. operates as an investment holding company. It is engaged in developing and commercializing blood-based miRNA test kit products for the early detection of cancer and other diseases. The firm’s business segments include Infectious Diseases and Early Detection and Precision Multi-Omics. The Infectious Diseases segment engages in development, manufacture, supply of diagnostic kits and provision of infectious disease clinical testing. The Early Detection and Precision Multi-Omics involves in Development, manufacture, supply of diagnostic & life sciences products, and provision of research profiling, clinical testing and clinical services. The company was founded by Too Heng Phon, Zhou Lihan and Zou Ruiyang in 2014 and is headquartered in Singapore. | Finance |
- Borsa valori
- Insiders
- Tai San Noah Lim
